


Waiv enters collaboration with Daiichi Sankyo to deliver AI-derived biomarkers for ADC programme

May 7, 2026 | News

Encompassing foundation models and AI methodology for ADC biomarker discovery programme



Waiv, formerly Owkin Dx, a Paris-based company catalysing artificial intelligence (AI) precision testing, has entered a collaboration with Japan-based Daiichi Sankyo to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) programme.

With deep expertise across diverse pathology and multimodal data, and a global data network spanning academic institutions, hospitals, and laboratories, Waiv has a proven track record delivering AI-powered biomarker solutions across the full drug development lifecycle.

Under the collaboration, Waiv will apply its end-to-end computational pathology platform to early phase data. This includes tumour microenvironment (TME) analysis across both hematoxylin and eosin (H&E) and immunohistochemistry (IHC) stained samples, as well as biomarker discovery and outcome prediction capabilities aimed at identifying biomarkers of treatment response ahead of next clinical trial phases.

Waiv's computational pathology platform is designed specifically for data-constrained settings, underpinned by a suite of foundation models developed across hundreds of thousands of images from its international data network. Its approach combines:

- Developing bespoke AI models optimised for low-data environments
- Extracting predictive signals directly from whole slide images across H&E and IHC stained samples
- Identifying novel histopathological biomarkers beyond predefined features
- Delivering reproducible, interpretable outputs suitable for clinical decision-making